{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T06:51:47Z","timestamp":1776840707498,"version":"3.51.2"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,21]]},"DOI":"10.7759\/cureus.107513","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:52:46Z","timestamp":1776837166000},"source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Efficacy of Nanodrug Delivery Compared With Current Nonsurgical Treatments for Patients With Cutaneous Melanoma: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Zarish","family":"Hussain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nujood","family":"Buhaimed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Al Khalifa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawaher","family":"Aljalahma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bedoor","family":"Alomran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Cancer today. Global Cancer Observatory. (2023). Accessed. February 20, 2023: https:\/\/gco.iarc.fr\/today\/online-analysis-pie."},{"key":"ref2","unstructured":"National Cancer Institute. melanoma of the skin-cancer stat facts. (2021). Accessed: May 10, 2021: https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176129","article-title":"Elucidation of melanogenesis cascade for identifying pathophysiology and therapeutic approach of pigmentary disorders and melanoma","volume":"21","author":"Hida T","year":"2020","unstructured":"Hida T, Kamiya T, Kawakami A, Ogino J, Sohma H, Uhara H, Jimbow K. Elucidation of melanogenesis cascade for identifying pathophysiology and therapeutic approach of pigmentary disorders and melanoma. Int J Mol Sci. 2020, 21:6129. 10.3390\/ijms21176129","journal-title":"Int J Mol Sci"},{"key":"ref4","article-title":"Melanoma development: current knowledge on melanoma pathogenesis","volume":"27","author":"Vukovi\u0107 P","year":"2019","unstructured":"Vukovi\u0107 P, Lugovi\u0107-Mihi\u0107 L, \u0106esi\u0107 D, Novak-Bili\u0107 G, \u0160itum M, Spoljar S. Melanoma development: current knowledge on melanoma pathogenesis. Acta Dermatovenerol Croat. 2019, 27:163.","journal-title":"Acta Dermatovenerol Croat"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061566","article-title":"Cutaneous melanoma-a long road from experimental models to clinical outcome: a review","volume":"19","author":"Coricovac D","year":"2018","unstructured":"Coricovac D, Dehelean C, Moaca EA, Pinzaru I, Bratu T, Navolan D, Boruga O. Cutaneous melanoma-a long road from experimental models to clinical outcome: a review. Int J Mol Sci. 2018, 19:1566. 10.3390\/ijms19061566","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20427","article-title":"Melanoma pathology: new approaches and classification","volume":"185","author":"Yeh I","year":"2021","unstructured":"Yeh I, Bastian BC. Melanoma pathology: new approaches and classification. Br J Dermatol. 2021, 185:282-93. 10.1111\/bjd.20427","journal-title":"Br J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s1085-5629(97)80008-9","article-title":"Variants of melanoma","volume":"16","author":"Reed RJ","year":"1997","unstructured":"Reed RJ, Martin P. Variants of melanoma. Semin Cutan Med Surg. 1997, 16:137-58. 10.1016\/s1085-5629(97)80008-9","journal-title":"Semin Cutan Med Surg"},{"key":"ref8","unstructured":"Melanoma. clinical features and diagnosis. (2022). Accessed: February 13, 2023: https:\/\/www.uptodate.com\/contents\/melanoma-clinical-features-and-diagnosis?search=melanoma&amp;source=search_result&amp;selec...."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.22.2771","article-title":"Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria","volume":"292","author":"Abbasi NR","year":"2004","unstructured":"Abbasi NR, Shaw HM, Rigel DS, et al.. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. 2004, 292:2771-6. 10.1001\/jama.292.22.2771","journal-title":"JAMA"},{"key":"ref10","unstructured":"Overview of dermoscopy. (2023). Accessed. February 13, 2023: https:\/\/www.uptodate.com\/contents\/overview-of-dermoscopy#:~:text=Dermoscopy%20is%20a%20noninvasive%2C%20in,handheld%2...."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2035","article-title":"Metastatic melanoma - a review of current and future treatment options","volume":"95","author":"Maverakis E","year":"2015","unstructured":"Maverakis E, Cornelius LA, Bowen GM, et al.. Metastatic melanoma - a review of current and future treatment options. Acta Derm Venereol. 2015, 95:516-24. 10.2340\/00015555-2035","journal-title":"Acta Derm Venereol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e3283632cbe","article-title":"Pulmonary metastasectomy for malignant melanoma: prognostic factors for long-term survival","volume":"23","author":"Younes R","year":"2013","unstructured":"Younes R, Abrao FC, Gross J. Pulmonary metastasectomy for malignant melanoma: prognostic factors for long-term survival. Melanoma Res. 2013, 23:307-11. 10.1097\/CMR.0b013e3283632cbe","journal-title":"Melanoma Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9040063","article-title":"Epidemiology of melanoma","volume":"9","author":"Saginala K","year":"2021","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A. Epidemiology of melanoma. Med Sci (Basel). 2021, 9:63. 10.3390\/medsci9040063","journal-title":"Med Sci (Basel)"},{"key":"ref14","article-title":"Nanoparticles in modern medicine: state of the art and future challenges","volume":"2","author":"Murthy SK","year":"2007","unstructured":"Murthy SK. Nanoparticles in modern medicine: state of the art and future challenges. Int J Nanomedicine. 2007, 2:129-41.","journal-title":"Int J Nanomedicine"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020318","article-title":"Nanosystems for improved targeted therapies in melanoma","volume":"9","author":"Beiu C","year":"2020","unstructured":"Beiu C, Giurcaneanu C, Grumezescu AM, Holban AM, Popa LG, Mihai MM. Nanosystems for improved targeted therapies in melanoma. J Clin Med. 2020, 9:318. 10.3390\/jcm9020318","journal-title":"J Clin Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/895986","article-title":"Drug delivery nanoparticles in skin cancers","volume":"2014","author":"Dianzani C","year":"2014","unstructured":"Dianzani C, Zara GP, Maina G, et al.. Drug delivery nanoparticles in skin cancers. Biomed Res Int. 2014, 2014:895986. 10.1155\/2014\/895986","journal-title":"Biomed Res Int"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2021.06.014","article-title":"Skin cancer biology and barriers to treatment: recent applications of polymeric micro\/nanostructures","volume":"36","author":"Khan NH","year":"2022","unstructured":"Khan NH, Mir M, Qian L, et al.. Skin cancer biology and barriers to treatment: recent applications of polymeric micro\/nanostructures. J Adv Res. 2022, 36:223-47. 10.1016\/j.jare.2021.06.014","journal-title":"J Adv Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/v12010035","article-title":"Virus-like particles and nanoparticles for vaccine development against HCMV","volume":"12","author":"Perotti M","year":"2019","unstructured":"Perotti M, Perez L. Virus-like particles and nanoparticles for vaccine development against HCMV. Viruses. 2019, 12:35. 10.3390\/v12010035","journal-title":"Viruses"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher D","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009, 6:e1000097. 10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181f1d614","article-title":"Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients","volume":"33","author":"Speiser DE","year":"2010","unstructured":"Speiser DE, Schwarz K, Baumgaertner P, et al.. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother. 2010, 33:848-58. 10.1097\/CJI.0b013e3181f1d614","journal-title":"J Immunother"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201142361","article-title":"Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8\u207a T-cell responses in melanoma patients","volume":"42","author":"Goldinger SM","year":"2012","unstructured":"Goldinger SM, Dummer R, Baumgaertner P, et al.. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8\u207a T-cell responses in melanoma patients. Eur J Immunol. 2012, 42:3049-61. 10.1002\/eji.201142361","journal-title":"Eur J Immunol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25659","article-title":"A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1)","volume":"117","author":"Kottschade LA","year":"2011","unstructured":"Kottschade LA, Suman VJ, Amatruda T 3rd, et al.. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1). Cancer. 2011, 117:1704-10. 10.1002\/cncr.25659","journal-title":"Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27760","article-title":"A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775","volume":"119","author":"Kottschade LA","year":"2013","unstructured":"Kottschade LA, Suman VJ, Perez DG, et al.. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer. 2013, 119:586-92. 10.1002\/cncr.27760","journal-title":"Cancer"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000062","article-title":"Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-\u03b1 in patients with metastatic melanoma","volume":"24","author":"Alrwas A","year":"2014","unstructured":"Alrwas A, Papadopoulos NE, Cain S, et al.. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-\u03b1 in patients with metastatic melanoma. Melanoma Res. 2014, 24:342-8. 10.1097\/CMR.0000000000000062","journal-title":"Melanoma Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24720","article-title":"A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma","volume":"116","author":"Hersh EM","year":"2010","unstructured":"Hersh EM, O'Day SJ, Ribas A, et al.. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer. 2010, 116:155-63. 10.1002\/cncr.24720","journal-title":"Cancer"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv324","article-title":"A randomized, controlled phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-na\u00efve patients with metastatic melanoma","volume":"26","author":"Hersh EM","year":"2015","unstructured":"Hersh EM, Del Vecchio M, Brown MP, et al.. A randomized, controlled phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-na\u00efve patients with metastatic melanoma. Ann Oncol. 2015, 26:2267-74. 10.1093\/annonc\/mdv324","journal-title":"Ann Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200510000-00015","article-title":"Phase II trial of weekly paclitaxel in patients with advanced melanoma","volume":"15","author":"Walker L","year":"2005","unstructured":"Walker L, Schalch H, King DM, et al.. Phase II trial of weekly paclitaxel in patients with advanced melanoma. Melanoma Res. 2005, 15:453-9. 10.1097\/00008390-200510000-00015","journal-title":"Melanoma Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900601)65:11<2478::AID-CNCR2820651114>3.0.CO;2-S","article-title":"A phase II trial of Taxol in metastatic melanoma","volume":"65","author":"Legha SS","year":"1990","unstructured":"Legha SS, Ring S, Papadopoulos N, et al.. A phase II trial of Taxol in metastatic melanoma. Cancer. 1990, 65:2478-81. 10.1002\/1097-0142(19900601)65:11&lt;2478::AID-CNCR2820651114&gt;3.0.CO;2-S","journal-title":"Cancer"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/BF00194546","article-title":"A phase II study of Taxol in patients with malignant melanoma","volume":"9","author":"Einzig AI","year":"1991","unstructured":"Einzig AI, Hochster H, Wiernik PH, et al.. A phase II study of Taxol in patients with malignant melanoma. Invest New Drugs. 1991, 9:59-64. 10.1007\/BF00194546","journal-title":"Invest New Drugs"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial","volume":"30","author":"Socinski MA","year":"2012","unstructured":"Socinski MA, Bondarenko I, Karaseva NA, et al.. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012, 30:2055-62. 10.1200\/JCO.2011.39.5848","journal-title":"J Clin Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.304","article-title":"Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel","volume":"54","author":"Chen N","year":"2014","unstructured":"Chen N, Li Y, Ye Y, Palmisano M, Chopra R, Zhou S. Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. J Clin Pharmacol. 2014, 54:1097-107. 10.1002\/jcph.304","journal-title":"J Clin Pharmacol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.06.030","article-title":"Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes","volume":"42","author":"Mielke S","year":"2006","unstructured":"Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer. 2006, 42:24-30. 10.1016\/j.ejca.2005.06.030","journal-title":"Eur J Cancer"},{"key":"ref35","doi-asserted-by":"crossref","DOI":"10.1016\/S1548-5315(11)70224-8","article-title":"Cremophor EL-containing paclitaxel-induced anaphylaxis: a call to action","volume":"6","author":"Irizarry LD","year":"2009","unstructured":"Irizarry LD, Luu TH, McKoy JM, et al.. Cremophor EL-containing paclitaxel-induced anaphylaxis: a call to action. Community Oncol. 2009, 6:132-4.","journal-title":"Community Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2009.06.022","article-title":"Nanoparticles evading the reticuloendothelial system: role of the supported bilayer","volume":"1788","author":"Li SD","year":"2009","unstructured":"Li SD, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta. 2009, 1788:2259-66. 10.1016\/j.bbamem.2009.06.022","journal-title":"Biochim Biophys Acta"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF V600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto PA","year":"2016","unstructured":"Ascierto PA, McArthur GA, Dre \u0301no B, et al.. Cobimetinib combined with vemurafenib in advanced BRAF V600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016, 17:1248-60. 10.1016\/S1470-2045(16)30122-X","journal-title":"Lancet Oncol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2008.12.004","article-title":"Nanoparticle-based targeted drug delivery","volume":"86","author":"Singh R","year":"2009","unstructured":"Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009, 86:215-23. 10.1016\/j.yexmp.2008.12.004","journal-title":"Exp Mol Pathol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100889","article-title":"Precision medicine: ray of hope in overcoming cancer multidrug resistance","volume":"65","author":"Musyuni P","year":"2022","unstructured":"Musyuni P, Bai J, Sheikh A, et al.. Precision medicine: ray of hope in overcoming cancer multidrug resistance. Drug Resist Updat. 2022, 65:100889. 10.1016\/j.drup.2022.100889","journal-title":"Drug Resist Updat"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0442-7","article-title":"A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors","volume":"6","author":"Verma V","year":"2018","unstructured":"Verma V, Sprave T, Haque W, Simone CB 2nd, Chang JY, Welsh JW, Thomas CR Jr. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018, 6:128. 10.1186\/s40425-018-0442-7","journal-title":"J Immunother Cancer"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.7150\/thno.49577","article-title":"The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy","volume":"10","author":"Shi Y","year":"2020","unstructured":"Shi Y, van der Meel R, Chen X, Lammers T. The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics. 2020, 10:7921-4. 10.7150\/thno.49577","journal-title":"Theranostics"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/468791-therapeutic-efficacy-of-nanodrug-delivery-compared-with-current-nonsurgical-treatments-for-patients-with-cutaneous-melanoma-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:52:56Z","timestamp":1776837176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/468791-therapeutic-efficacy-of-nanodrug-delivery-compared-with-current-nonsurgical-treatments-for-patients-with-cutaneous-melanoma-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.107513","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}